CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key market segments
1.3.Key benefits to the stakeholders
1.4.Research Methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO Perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.3.Porter’s five forces analysis
3.4.Top player positioning
3.5.Market dynamics
3.5.1.Drivers
3.5.2.Restraints
3.5.3.Opportunities
3.6.COVID-19 Impact Analysis on the market
CHAPTER 4: ALZHEIMER’S THERAPEUTICS MARKET, BY DRUG CLASS
4.1 Overview
4.1.1 Market size and forecast
4.2 Cholinesterase inhibitors
4.2.1 Key market trends, growth factors and opportunities
4.2.2 Market size and forecast, by region
4.2.3 Market analysis by country
4.3 N-Methyl-D-Aspartate (NMDA) receptor antagonist
4.3.1 Key market trends, growth factors and opportunities
4.3.2 Market size and forecast, by region
4.3.3 Market analysis by country
4.4 Others
4.4.1 Key market trends, growth factors and opportunities
4.4.2 Market size and forecast, by region
4.4.3 Market analysis by country
CHAPTER 5: ALZHEIMER’S THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL
5.1 Overview
5.1.1 Market size and forecast
5.2 Hospital Pharmacy
5.2.1 Key market trends, growth factors and opportunities
5.2.2 Market size and forecast, by region
5.2.3 Market analysis by country
5.3 Drug Store and Retail Pharmacy
5.3.1 Key market trends, growth factors and opportunities
5.3.2 Market size and forecast, by region
5.3.3 Market analysis by country
5.4 Online Pharmacy
5.4.1 Key market trends, growth factors and opportunities
5.4.2 Market size and forecast, by region
5.4.3 Market analysis by country
CHAPTER 6: ALZHEIMER’S THERAPEUTICS MARKET, BY REGION
6.1 Overview
6.1.1 Market size and forecast
6.2 North America
6.2.1 Key trends and opportunities
6.2.2 North America Market size and forecast, by Drug Class
6.2.3 North America Market size and forecast, by Distribution Channel
6.2.4 North America Market size and forecast, by country
6.2.4.1 U.S.
6.2.4.1.1 Market size and forecast, by Drug Class
6.2.4.1.2 Market size and forecast, by Distribution Channel
6.2.4.2 Canada
6.2.4.2.1 Market size and forecast, by Drug Class
6.2.4.2.2 Market size and forecast, by Distribution Channel
6.2.4.3 Mexico
6.2.4.3.1 Market size and forecast, by Drug Class
6.2.4.3.2 Market size and forecast, by Distribution Channel
6.3 Europe
6.3.1 Key trends and opportunities
6.3.2 Europe Market size and forecast, by Drug Class
6.3.3 Europe Market size and forecast, by Distribution Channel
6.3.4 Europe Market size and forecast, by country
6.3.4.1 Germany
6.3.4.1.1 Market size and forecast, by Drug Class
6.3.4.1.2 Market size and forecast, by Distribution Channel
6.3.4.2 France
6.3.4.2.1 Market size and forecast, by Drug Class
6.3.4.2.2 Market size and forecast, by Distribution Channel
6.3.4.3 UK
6.3.4.3.1 Market size and forecast, by Drug Class
6.3.4.3.2 Market size and forecast, by Distribution Channel
6.3.4.4 Italy
6.3.4.4.1 Market size and forecast, by Drug Class
6.3.4.4.2 Market size and forecast, by Distribution Channel
6.3.4.5 Spain
6.3.4.5.1 Market size and forecast, by Drug Class
6.3.4.5.2 Market size and forecast, by Distribution Channel
6.3.4.6 Rest of Europe
6.3.4.6.1 Market size and forecast, by Drug Class
6.3.4.6.2 Market size and forecast, by Distribution Channel
6.4 Asia-Pacific
6.4.1 Key trends and opportunities
6.4.2 Asia-Pacific Market size and forecast, by Drug Class
6.4.3 Asia-Pacific Market size and forecast, by Distribution Channel
6.4.4 Asia-Pacific Market size and forecast, by country
6.4.4.1 Japan
6.4.4.1.1 Market size and forecast, by Drug Class
6.4.4.1.2 Market size and forecast, by Distribution Channel
6.4.4.2 China
6.4.4.2.1 Market size and forecast, by Drug Class
6.4.4.2.2 Market size and forecast, by Distribution Channel
6.4.4.3 Australia
6.4.4.3.1 Market size and forecast, by Drug Class
6.4.4.3.2 Market size and forecast, by Distribution Channel
6.4.4.4 India
6.4.4.4.1 Market size and forecast, by Drug Class
6.4.4.4.2 Market size and forecast, by Distribution Channel
6.4.4.5 South Korea
6.4.4.5.1 Market size and forecast, by Drug Class
6.4.4.5.2 Market size and forecast, by Distribution Channel
6.4.4.6 Rest of Asia-Pacific
6.4.4.6.1 Market size and forecast, by Drug Class
6.4.4.6.2 Market size and forecast, by Distribution Channel
6.5 LAMEA
6.5.1 Key trends and opportunities
6.5.2 LAMEA Market size and forecast, by Drug Class
6.5.3 LAMEA Market size and forecast, by Distribution Channel
6.5.4 LAMEA Market size and forecast, by country
6.5.4.1 Brazil
6.5.4.1.1 Market size and forecast, by Drug Class
6.5.4.1.2 Market size and forecast, by Distribution Channel
6.5.4.2 Saudi Arabia
6.5.4.2.1 Market size and forecast, by Drug Class
6.5.4.2.2 Market size and forecast, by Distribution Channel
6.5.4.3 South Africa
6.5.4.3.1 Market size and forecast, by Drug Class
6.5.4.3.2 Market size and forecast, by Distribution Channel
6.5.4.4 Rest of LAMEA
6.5.4.4.1 Market size and forecast, by Drug Class
6.5.4.4.2 Market size and forecast, by Distribution Channel
CHAPTER 7: COMPANY LANDSCAPE
7.1. Introduction
7.2. Top winning strategies
7.3. Product Mapping of Top 10 Player
7.4. Competitive Dashboard
7.5. Competitive Heatmap
7.6. Key developments
CHAPTER 8: COMPANY PROFILES
8.1 Biogen
8.1.1 Company overview
8.1.2 Company snapshot
8.1.3 Operating business segments
8.1.4 Product portfolio
8.1.5 Business performance
8.1.6 Key strategic moves and developments
8.2 Merck & Co. Inc.
8.2.1 Company overview
8.2.2 Company snapshot
8.2.3 Operating business segments
8.2.4 Product portfolio
8.2.5 Business performance
8.2.6 Key strategic moves and developments
8.3 Novartis AG
8.3.1 Company overview
8.3.2 Company snapshot
8.3.3 Operating business segments
8.3.4 Product portfolio
8.3.5 Business performance
8.3.6 Key strategic moves and developments
8.4 Eisai Co. Ltd.
8.4.1 Company overview
8.4.2 Company snapshot
8.4.3 Operating business segments
8.4.4 Product portfolio
8.4.5 Business performance
8.4.6 Key strategic moves and developments
8.5 H. Lundbeck A/S
8.5.1 Company overview
8.5.2 Company snapshot
8.5.3 Operating business segments
8.5.4 Product portfolio
8.5.5 Business performance
8.5.6 Key strategic moves and developments
8.6 DAIICHI SANKYO COMPANY, LIMITED
8.6.1 Company overview
8.6.2 Company snapshot
8.6.3 Operating business segments
8.6.4 Product portfolio
8.6.5 Business performance
8.6.6 Key strategic moves and developments
8.7 AbbVie Inc.
8.7.1 Company overview
8.7.2 Company snapshot
8.7.3 Operating business segments
8.7.4 Product portfolio
8.7.5 Business performance
8.7.6 Key strategic moves and developments
8.8 Teva Pharmaceuticals Industries Ltd.
8.8.1 Company overview
8.8.2 Company snapshot
8.8.3 Operating business segments
8.8.4 Product portfolio
8.8.5 Business performance
8.8.6 Key strategic moves and developments
8.9 Eli Lilly and Company
8.9.1 Company overview
8.9.2 Company snapshot
8.9.3 Operating business segments
8.9.4 Product portfolio
8.9.5 Business performance
8.9.6 Key strategic moves and developments
8.10 Lupin Ltd
8.10.1 Company overview
8.10.2 Company snapshot
8.10.3 Operating business segments
8.10.4 Product portfolio
8.10.5 Business performance
8.10.6 Key strategic moves and developments
❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
